Schellenberg Wittmer has advised BNP Paribas (Suisse) in the placement of Equinix‘ debut Swiss bond issuance. BNP Paribas (Suisse) acted as Swiss paying agent and, together with Deutsche Bank London branch, acting through Deutsche Bank
Tags :Schellenberg Wittmer
Schellenberg Wittmer‘s Singapore office celebrates its tenth anniversary in the Asian country. In 2013, partner Philippe Borens opened the office and laid the foundations for a thriving business. Partner Christopher Boog took over as managing
Schellenberg Wittmer has provided legal counsel to Santhera Pharmaceuticals Holding in the sale of its Raxone®/idebenone business for all indications worldwide to Chiesi Farmaceutici. The deal marks a significant update to the existing license
Schellenberg Wittmer‘s partners Christopher Boog and Elliott Geisinger have been acknowledged on this list of the Top 10 Most Influential Swiss Arbitration Counsels. Christopher Boog is a Vice-Chair of Schellenberg Wittmer’s International arbitration practice
Schellenberg Wittmer strengthens its team with new appointments. Karina Beaud, Janine Haesler, Kevin Laurent, Nina Lumengo Paka, Manuela Scerri and Daniil Vlasenko are promoted to Senior Associates as of 1 July 2023. Karina Beaud (pictured top left)
Schellenberg Wittmer has advised BNP Paribas Suisse in the placement of CHF 410 million dual tranche senior fixed rate notes issued by EnBW International Finance. BNP Paribas Suisse acted as Swiss paying agent and, together with
Schellenberg Wittmer advised Swisscanto Private Equity in the CHF 8.3 million Series B financing of the renowned innovator in ultrasonic camera technology Distran, an ETH Zürich spin-off. The funding will be deployed to fuel the
Schellenberg Wittmer advised Geneva based Thematica in obtaining its FINMA license as manager of collective assets with the Swiss Financial Markets Supervisory Authority (FINMA). Founded in 2006, Thematica specializes in tailored investment solutions for professional clients
Schellenberg Wittmer acted as Swiss counsel to SPRIM Global Investments (SGI), a leading health sciences venture capital firm, in its capital commitment of USD 4.5 million in favor of Spexis, a clinical-stage and biopharmaceutical company listed
Santhera Pharmaceuticals Holding has announced the grant of an exclusive North America license for the commercialization of vamorolone to Catalyst Pharmaceuticals for a total consideration of up to USD 231 million
